MCID: PLM014
MIFTS: 55

Pleomorphic Adenoma

Categories: Endocrine diseases, Cancer diseases

Aliases & Classifications for Pleomorphic Adenoma

MalaCards integrated aliases for Pleomorphic Adenoma:

Name: Pleomorphic Adenoma 12 14
Mixed Tumor, Not Otherwise Specified 69
Mixed Tumor of the Salivary Gland 12
Mixed Salivary Gland Tumor 69
Adenoma, Pleomorphic 41
Adenoma Pleomorphic 51

Classifications:



External Ids:

Disease Ontology 12 DOID:452
MeSH 41 D008949
NCIt 46 C35691 C8602
SNOMED-CT 64 8360001

Summaries for Pleomorphic Adenoma

Disease Ontology : 12 A gastrointestinal benign neoplasm that is a located in the salivary glands.

MalaCards based summary : Pleomorphic Adenoma, also known as mixed tumor, not otherwise specified, is related to salivary gland adenoma, pleomorphic and adenoma. An important gene associated with Pleomorphic Adenoma is PLAG1 (PLAG1 Zinc Finger), and among its related pathways/superpathways are DNA Damage and Development EGFR signaling pathway. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include the salivary gl, salivary gland and uterus, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 72 Pleomorphic adenoma is a common benign salivary gland neoplasm characterised by neoplastic proliferation... more...

Related Diseases for Pleomorphic Adenoma

Diseases related to Pleomorphic Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 250)
# Related Disease Score Top Affiliating Genes
1 salivary gland adenoma, pleomorphic 32.2 HMGA2 PLAG1 S100B
2 adenoma 31.9 PLAG1 PLAGL1 PLAGL2 TP53
3 epithelial-myoepithelial carcinoma 30.7 HMGA2 KRT14 TP53
4 fasciitis 30.3 ACTC1 MUC1 VIM
5 nodular hidradenoma 30.2 MUC1 VIM
6 neurilemmoma 30.2 GFAP S100B VIM
7 chordoma 30.1 GFAP MUC1 S100B VIM
8 lipomatosis, multiple 30.1 HMGA2 MDM2 PLAG1
9 mesenchymoma 30.0 HMGA2 MDM2
10 in situ carcinoma 29.9 ERBB2 KRT14 TP53
11 squamous cell carcinoma 29.9 ERBB2 MUC1 TP53 TP63
12 myxoid liposarcoma 29.8 HMGA2 MDM2 TP53
13 spindle cell lipoma 29.7 ACTC1 MDM2 VIM
14 mucoepidermoid carcinoma 29.7 ACTC1 ERBB2 KRT14 MUC1 TP63
15 liposarcoma 29.6 HMGA2 MDM2 TP53 VIM
16 astrocytoma 29.4 GFAP MDM2 S100B TP53 VIM
17 hemangiopericytoma, malignant 29.3 ACTC1 MDM2 MUC1 S100B VIM
18 syringoma 29.2 GFAP MUC1 S100B SERPINB5 TP63 VIM
19 polymorphous low-grade adenocarcinoma 29.0 ACTC1 MUC1 S100B SERPINB5 TP63 VIM
20 myoepithelioma 28.9 ACTC1 GFAP KRT14 S100B SERPINB5 TP63
21 pleomorphic adenoma carcinoma 12.3
22 mixed lacrimal gland cancer 11.5
23 frontal convexity meningioma 10.6 GFAP TP53
24 gliofibroma 10.6 GFAP TP53
25 hydromyelia 10.6 S100B VIM
26 primitive neuroectodermal tumor of the cervix uteri 10.6 GFAP VIM
27 cerebral convexity meningioma 10.6 GFAP TP53
28 protoplasmic astrocytoma 10.6 GFAP TP53
29 bednar tumor 10.6 S100B VIM
30 cellular ependymoma 10.5 GFAP TP53
31 localized hypertrophic neuropathy 10.5 MUC1 S100B
32 sclerosing perineurioma 10.5 MUC1 S100B
33 primary hepatic neuroendocrine carcinoma 10.5 S100B VIM
34 reticular perineurioma 10.5 MUC1 S100B
35 rhabdoid meningioma 10.5 GFAP VIM
36 malignant peritoneal mesothelioma 10.5 MUC1 VIM
37 gemistocytic astrocytoma 10.5 GFAP S100B
38 papillary tumor of the pineal region 10.5 MUC1 VIM
39 non-functioning pituitary adenoma 10.5 MUC1 S100B
40 central nervous system primitive neuroectodermal neoplasm 10.5 GFAP TP53
41 biphasic synovial sarcoma 10.5 MUC1 VIM
42 lymphangiectasis 10.5 ACTC1 VIM
43 uterine corpus serous adenocarcinoma 10.4 ERBB2 TP53
44 ependymoblastoma 10.4 GFAP TP53 VIM
45 spindle cell rhabdomyosarcoma 10.4 GFAP MUC1
46 malignant mixed mullerian tumor 10.4 MUC1 VIM
47 epithelioid malignant peripheral nerve sheath tumor 10.4 MUC1 S100B
48 glioma susceptibility 1 10.4 ERBB2 TP53
49 glomangiomyoma 10.4 ACTC1 VIM
50 granular cell tumor 10.4 GFAP S100B VIM

Graphical network of the top 20 diseases related to Pleomorphic Adenoma:



Diseases related to Pleomorphic Adenoma

Symptoms & Phenotypes for Pleomorphic Adenoma

GenomeRNAi Phenotypes related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

25 (show all 25)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.84 S100B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.84 VIM
3 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.84 PLAGL2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.84 PLAG1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.84 PLAGL2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.84 PLAGL2 VIM
7 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.84 PLAG1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.84 ERBB2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.84 ERBB2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.84 ERBB2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.84 VIM
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.84 VIM
13 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.84 VIM
14 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.84 VIM
15 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.84 PLAG1 ERBB2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.84 PLAGL2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.84 VIM
18 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.84 VIM
19 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.84 ERBB2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.84 PLAG1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.84 PLAGL2 S100B VIM ERBB2 PLAG1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.84 PLAGL2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.84 PLAGL2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.84 S100B VIM ERBB2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.84 PLAG1

MGI Mouse Phenotypes related to Pleomorphic Adenoma:

43 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.26 PLAGL1 TP63 MDM2 SERPINB5 TP53 VIM
2 growth/size/body region MP:0005378 10.23 PLAGL1 TP63 PLAGL2 SERPINB5 TP53 PLAG1
3 cardiovascular system MP:0005385 10.19 PLAGL1 TP63 MDM2 TP53 VIM GFAP
4 homeostasis/metabolism MP:0005376 10.17 TP53 PLAGL2 S100B TP63 MDM2 VIM
5 embryo MP:0005380 10.13 PLAGL1 TP63 SERPINB5 TP53 PLAG1 VIM
6 digestive/alimentary MP:0005381 10.1 TP63 PLAGL2 TP53 KRT14 ERBB2 MDM2
7 mortality/aging MP:0010768 10.1 PLAGL1 PLAGL2 TP63 MDM2 SERPINB5 TP53
8 integument MP:0010771 10.01 PLAGL1 TP63 S100B MDM2 TP53 AR
9 craniofacial MP:0005382 9.99 TP53 MDM2 TP63 AR KRT14 ERBB2
10 muscle MP:0005369 9.86 TP63 MDM2 TP53 VIM AR ERBB2
11 limbs/digits/tail MP:0005371 9.85 TP53 PLAGL1 MDM2 TP63 AR ERBB2
12 neoplasm MP:0002006 9.63 TP53 MDM2 TP63 AR KRT14 ERBB2
13 normal MP:0002873 9.61 TP63 S100B SERPINB5 TP53 ERBB2 MDM2
14 reproductive system MP:0005389 9.23 PLAG1 TP53 MDM2 TP63 VIM AR

Drugs & Therapeutics for Pleomorphic Adenoma

Drugs for Pleomorphic Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
4
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
5 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
6 Antimitotic Agents Phase 3,Phase 2,Phase 1
7 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
8 Alkylating Agents Phase 3,Phase 2
9 Isophosphamide mustard Phase 3,Phase 2 0
10
Gemcitabine Approved Phase 2 95058-81-4 60750
11
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
12
Mesna Approved, Investigational Phase 2 3375-50-6 598
13
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
14
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
15
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
16
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
17
Everolimus Approved Phase 2 159351-69-6 6442177
18
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
19
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
20
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
21
Metformin Approved Phase 2 657-24-9 4091 14219
22
nivolumab Approved Phase 2 946414-94-4
23
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
24
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
26
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
27
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
28
Doxil Approved June 1999 Phase 2 31703
29
Docetaxel Approved May 1996, Investigational Phase 2,Phase 1 114977-28-5 148124 9877265
30
Saracatinib Investigational Phase 2 379231-04-6
31
Tremelimumab Investigational Phase 2 745013-59-6
32 Anti-Infective Agents Phase 2
33 Antimetabolites Phase 2,Phase 1
34 Antimetabolites, Antineoplastic Phase 2,Phase 1
35 Antiviral Agents Phase 2
36 Immunosuppressive Agents Phase 2,Phase 1
37 Protein Kinase Inhibitors Phase 2,Phase 1
38 Epothilones Phase 2,Phase 1
39 Anti-Bacterial Agents Phase 2
40 Antibiotics, Antitubercular Phase 2
41 Topoisomerase Inhibitors Phase 2
42
iniparib Phase 2
43 Poly(ADP-ribose) Polymerase Inhibitors Phase 2,Phase 1
44 Imatinib Mesylate Phase 2 123596
45 Angiogenesis Inhibitors Phase 2,Phase 1
46 Angiogenesis Modulating Agents Phase 2,Phase 1
47 Micronutrients Phase 2
48 Nicotinic Acids Phase 2
49 Trace Elements Phase 2
50 Vitamin B Complex Phase 2

Interventional clinical trials:

(show all 50)

# Name Status NCT ID Phase Drugs
1 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
2 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
3 Quadrant Versus Superficial Parotidectomy Withdrawn NCT01607866 Phase 2, Phase 3
4 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
5 Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus Completed NCT00502203 Phase 2 Carboplatin;Paclitaxel
6 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2 gemcitabine
7 Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours Completed NCT00189410 Phase 2 Pegylated Liposomal Doxorubicin and Carboplatin
8 A Phase II Trial of Adjuvant Radiation Therapy With Ifosfamide in Patients With MMT of the Uterus Completed NCT00231842 Phase 2 Ifosfamide
9 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
10 Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus Completed NCT00476086 Phase 2 Gemcitabine;Oxaliplatin
11 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
12 Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2 paclitaxel;carboplatin;BSI-201 (Iniparib)
13 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
14 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00075400 Phase 2 imatinib mesylate
15 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
16 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Completed NCT00238121 Phase 2 sorafenib tosylate
17 Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors Completed NCT00520013 Phase 2 bevacizumab;erlotinib;paclitaxel;carboplatin
18 Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer Completed NCT00511992 Phase 2 Avastin;Paclitaxel;Cisplatin
19 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
20 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
21 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
22 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
23 A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Recruiting NCT03015129 Phase 2 Durvalumab;Tremelimumab
24 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
25 A Study of Nivolumab in Selected Uterine Cancer Patients Recruiting NCT03241745 Phase 2 Nivolumab
26 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
27 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02101775 Phase 2 Gemcitabine Hydrochloride;WEE1 Inhibitor AZD1775
28 Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Active, not recruiting NCT01168232 Phase 2 ixabepilone
29 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT00478426 Phase 2 Sunitinib Malate
30 Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26 Not yet recruiting NCT02993705 Phase 2 Trabectedin
31 Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Suspended NCT01935934 Phase 2 Cabozantinib S-malate
32 Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer Terminated NCT00322881 Phase 2 Paclitaxel;Carboplatin
33 Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy Terminated NCT00505492 Phase 2 Carboplatin;Cisplatin;Paclitaxel
34 Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus Terminated NCT01061606 Phase 2 temsirolimus
35 Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies Withdrawn NCT00984217 Phase 2 Panitumumab
36 A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma Unknown status NCT01454479 Phase 1 Lapatinib and ixempra
37 Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors Completed NCT00413322 Phase 1 belinostat;5-Fluorouracil (5-FU)
38 Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma Completed NCT00413075 Phase 1 oral belinostat
39 Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer Completed NCT00352300 Phase 1 Carboplatin;Paclitaxel
40 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
41 Suitability of DCE-MRI for Detection of Vascular Changes After VBT Recruiting NCT01991808 Phase 1
42 Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary Recruiting NCT03206177 Phase 1 Galunisertib;Paclitaxel;Carboplatin
43 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
44 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Suspended NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
45 Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer Unknown status NCT01367301 paclitaxel;carboplatin
46 Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer Recruiting NCT02983279
47 Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Active, not recruiting NCT01080521
48 Study of Imaging Characteristics OCT of Skin Lesions Requiring Biopsy / Resection Not yet recruiting NCT02851693
49 microRNA Profiles Identification in Adeno Carcinoma Prostate Cancer Not yet recruiting NCT02964351
50 Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient No longer available NCT02090127 ficlatuzumab

Search NIH Clinical Center for Pleomorphic Adenoma

Cochrane evidence based reviews: adenoma, pleomorphic

Genetic Tests for Pleomorphic Adenoma

Anatomical Context for Pleomorphic Adenoma

The Foundational Model of Anatomy Ontology organs/tissues related to Pleomorphic Adenoma:

18
The Salivary Gl

MalaCards organs/tissues related to Pleomorphic Adenoma:

38
Salivary Gland, Uterus, Breast, Liver, Prostate, Trachea, Bone

Publications for Pleomorphic Adenoma

Articles related to Pleomorphic Adenoma:

(show top 50) (show all 804)
# Title Authors Year
1
The Effectiveness of Sternocleidomastoid Flap Versus Superficial Musculoaponeurotic System Flap for the Prevention of Frey Syndrome and Facial Depressed Deformity in Parotid Surgery for Pleomorphic Adenoma. ( 29095193 )
2018
2
Pleomorphic Adenoma of Submandibular Gland with Extensive Cystic Keratinization. ( 29290205 )
2018
3
Promoter hypermethylation may contribute to Ea89cadherin repression in the human salivary carcinoma ex pleomorphic adenoma. ( 29207084 )
2018
4
Gray scale and doppler ultrasonography features of the carcinoma ex pleomorphic adenoma. ( 29365290 )
2018
5
Recurrent rearrangements of the PLAG1 and HMGA2 genes in lacrimal gland pleomorphic adenoma and carcinoma ex pleomorphic adenoma. ( 29437290 )
2018
6
Lacrimal myoepithelial carcinoma ex recurrent pleomorphic adenoma: A clinicopathological report and review of the literature. ( 29387416 )
2018
7
Epithelial-Myoepithelial Carcinoma: Frequent Morphologic and Molecular Evidence of Preexisting Pleomorphic Adenoma, Common HRAS Mutations in PLAG1-intact and HMGA2-intact Cases, and Occasional TP53, FBXW7, and SMARCB1 Alterations in High-grade Cases. ( 29135520 )
2018
8
Transnasal Endoscopic Resection of a Pleomorphic Adenoma Originate From Nasal Floor. ( 28857999 )
2017
9
Recurrent pleomorphic adenoma: is treatment considerably delayed thus affecting surgical morbidity? ( 29141486 )
2017
10
Clinicopathologic and Surgical Study of Pleomorphic Adenoma of the Parotid Gland: Analysis of Risk Factors for Recurrence and Facial Nerve Dysfunction. ( 28863883 )
2017
11
Increased SOX2 expression in salivary gland carcinoma ex pleomorphic adenoma progression: an association with adverse outcome. ( 28842747 )
2017
12
The recurrent pleomorphic adenoma conundrum. ( 29278551 )
2017
13
Largest De Novo Parapharyngeal Pleomorphic Adenoma: A Rare Case Removed Via Minimal Access Approach. ( 28713752 )
2017
14
The role of insulin-like growth factor I-II receptor on development of pleomorphic adenoma. ( 28625007 )
2017
15
BRCA1/2 Mutations in Salivary Pleomorphic Adenoma and Carcinoma-ex-Pleomorphic Adenoma. ( 29285471 )
2017
16
Prognostic nomogram for disease-specific survival of carcinoma ex pleomorphic adenoma of the salivary gland. ( 28945292 )
2017
17
The Effects of Platelet-Rich Fibrin Membrane on Secondary Healing After Pleomorphic Adenoma Excision in the Hard Palate: A Preliminary Study. ( 28713740 )
2017
18
The PRKD1 E710D hotspot mutation is highly specific in separating polymorphous adenocarcinoma of the palate from adenoid cystic carcinoma and pleomorphic adenoma on FNA. ( 29266837 )
2017
19
Correlation between computed tomography imaging and histopathology in pleomorphic adenoma of parotid gland. ( 29055657 )
2017
20
Intracapsular carcinoma ex-pleomorphic adenoma of the parapharyngeal space: report of two cases and review of the literature. ( 29143959 )
2017
21
Diffusion-weighted MRI for differentiation between sialadenitis and pleomorphic adenoma. ( 27845594 )
2017
22
Pleomorphic Adenoma of the Posterior Surface of the Soft Palate Causing Sleep Disturbance: A Case Report. ( 29187728 )
2017
23
Spontaneous Rupture of Lacrimal Gland Pleomorphic Adenoma: Pivotal Role in Masquerading Orbital Cellulitis. ( 29049099 )
2017
24
Low Grade Carcinoma Ex-Pleomorphic Adenoma: Diagnosis and Diagnostic Challenges Caused by Fine Needle Aspiration: Report of Three Cases and Review of Literature. ( 28589437 )
2017
25
Hemifacial Spasm Secondary to Parotid Pleomorphic Adenoma With Stylomastoid Foramen Extension. ( 27755360 )
2017
26
Pleomorphic Adenoma of an Accessory Lacrimal Gland Masquerading as a Chalazion. ( 28645342 )
2017
27
Metastasizing pleomorphic adenoma of the parotid gland. ( 28900471 )
2017
28
Volumetric Growth Rate of Recurrent Pleomorphic Adenoma. ( 28604082 )
2017
29
Pleomorphic Adenoma of Minor Salivary Glands in Child. ( 29284907 )
2017
30
Synchronous contralateral pleomorphic adenoma of the parotid gland and submandibular gland. ( 27914682 )
2017
31
Pleomorphic Adenoma Originating from Heterotopic Salivary Tissue of the Upper Neck: A Diagnostic Pitfall. ( 29270325 )
2017
32
Parapharyngeal space pleomorphic adenoma: a case report. ( 28690748 )
2017
33
Pleomorphic adenoma - the results of a retrospective analysis of 104 patients treated at the Clinical Department of Cranio-Maxillofacial Surgery, Clinic of Otolaryngology and Laryngologic Oncology of the Military Institute of Medicine. ( 29116049 )
2017
34
PLAG1 immunohistochemistry is a sensitive marker for Pleomorphic Adenoma: a comparative study with PLAG1 genetic abnormalities. ( 28796899 )
2017
35
A Case Report of Rare Carcinoma Ex Pleomorphic Adenoma of Submandibular Gland and its Detailed Description. ( 28658924 )
2017
36
Re: Endoscopically-assisted extracapsular dissection of pleomorphic adenoma of the parotid gland through a postauricular sulcus approach in young patients. ( 28735635 )
2017
37
Pleomorphic adenoma gene like-2 induces epithelial-mesenchymal transition via Wnt/I^-catenin signaling pathway in human colorectal adenocarcinoma. ( 28259923 )
2017
38
Carcinoma ex pleomorphic adenoma: case report and options for systemic therapy. ( 28680294 )
2017
39
Intraoral Pleomorphic Adenoma in Young Patients. ( 29227411 )
2017
40
Solitary fibrous tumor of the lacrimal gland mimicking pleomorphic adenoma. ( 28832740 )
2017
41
Giant pleomorphic adenoma of the lacrimal gland: A surgical challenge. ( 29039996 )
2017
42
Circulating high mobility group AT-hook 2 and pleomorphic adenoma gene 1 in blood of patients with oral squamous cell carcinoma. ( 28650082 )
2017
43
Giant Parapharyngeal Space Pleomorphic Adenoma Causing Acute Airway Obstruction. ( 28584606 )
2017
44
Combined salivary duct carcinoma and squamous cell carcinoma suspected of carcinoma ex pleomorphic adenoma. ( 27435055 )
2016
45
Pleomorphic Adenoma of the Eyelid with Apocrine Gland Origin; an Atypical Location. ( 27994815 )
2016
46
Twist Expression in Pleomorphic Adenoma, Adenoid Cystic Carcinoma and Mucoepidermoid Carcinoma of Salivary Glands. ( 26832177 )
2016
47
A rare carcinoma ex pleomorphic adenoma of the buccal minor salivary gland causing a therapeutic dilemma. ( 27146731 )
2016
48
Pleomorphic Adenoma in Retromolar Area: A Very Rare Case Report and Review of Literature. ( 26894184 )
2016
49
Giant parotid pleomorphic adenoma in a Nigerian male. ( 27538561 )
2016
50
Recurrent pleomorphic adenoma of the parotid gland: Institutional experience and review of the literature. ( 27468730 )
2016

Variations for Pleomorphic Adenoma

Cosmic variations for Pleomorphic Adenoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10808 TP53 salivary gland,parotid,adenoma,pleomorphic c.488A>G p.Y163C 15
2 COSM43909 TP53 salivary gland,parotid,adenoma,pleomorphic c.817C>A p.R273S 15
3 COSM6932 TP53 salivary gland,parotid,adenoma,myoepithelial c.733G>A p.G245S 11
4 COSM43635 TP53 salivary gland,parotid,adenoma,myoepithelial c.536A>T p.H179L 11
5 COSM13168 CTNNB1 salivary gland,parotid,adenoma,NS c.104T>C p.I35T 10
6 COSM5688 CTNNB1 salivary gland,parotid,adenoma,NS c.121A>C p.T41P 10
7 COSM21826 ATM salivary gland,parotid,adenoma,NS c.2572T>C p.F858L 10

Copy number variations for Pleomorphic Adenoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 239266 8 38279166 38315052 Gain FGFR1 Pleomorphic adenoma

Expression for Pleomorphic Adenoma

Search GEO for disease gene expression data for Pleomorphic Adenoma.

Pathways for Pleomorphic Adenoma

GO Terms for Pleomorphic Adenoma

Cellular components related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear chromatin GO:0000790 8.92 AR MUC1 TP53 TP63

Biological processes related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.95 AR HMGA2 PLAG1 PLAGL1 PLAGL2 TP53
2 apoptotic process GO:0006915 9.93 ACTC1 PLAG1 PLAGL1 PLAGL2 TP53 TP63
3 negative regulation of apoptotic process GO:0043066 9.92 ACTC1 HMGA2 MDM2 TP53 TP63
4 transcription by RNA polymerase II GO:0006366 9.85 HMGA2 PLAG1 PLAGL1 PLAGL2 TP53 TP63
5 cell proliferation GO:0008283 9.83 AR ERBB2 S100B TP53 TP63
6 cellular response to hypoxia GO:0071456 9.74 MDM2 S100B TP53
7 negative regulation of neuron projection development GO:0010977 9.65 GFAP MDM2 VIM
8 astrocyte development GO:0014002 9.6 GFAP VIM
9 positive regulation of protein export from nucleus GO:0046827 9.59 MDM2 TP53
10 intermediate filament organization GO:0045109 9.58 GFAP VIM
11 prostate gland development GO:0030850 9.58 AR TP63
12 positive regulation of glial cell proliferation GO:0060252 9.56 GFAP PLAG1
13 positive regulation of transcription by RNA polymerase III GO:0045945 9.55 AR ERBB2
14 mitotic G1 DNA damage checkpoint GO:0031571 9.54 TP53 TP63
15 Bergmann glial cell differentiation GO:0060020 9.51 GFAP VIM
16 prostate gland growth GO:0060736 9.49 AR PLAG1
17 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.33 MUC1 TP53 TP63
18 intermediate filament-based process GO:0045103 9.32 GFAP VIM
19 cellular response to actinomycin D GO:0072717 9.26 MDM2 TP53
20 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.26 MDM2 MUC1 PLAGL1 TP53
21 positive regulation of gene expression GO:0010628 9.23 ACTC1 AR ERBB2 HMGA2 MDM2 PLAG1
22 transcription, DNA-templated GO:0006351 10.21 AR ERBB2 HMGA2 PLAG1 PLAGL1 PLAGL2

Molecular functions related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.7 ERBB2 GFAP MDM2 S100B TP53 TP63
2 transcription regulatory region DNA binding GO:0044212 9.67 AR HMGA2 TP53 TP63
3 structural constituent of cytoskeleton GO:0005200 9.61 GFAP KRT14 VIM
4 transcription factor activity, transcription factor binding GO:0000989 9.4 HMGA2 TP63
5 transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding GO:0001077 9.35 AR HMGA2 PLAG1 PLAGL2 TP63
6 MDM2/MDM4 family protein binding GO:0097371 9.32 TP53 TP63
7 keratin filament binding GO:1990254 9.26 KRT14 VIM
8 p53 binding GO:0002039 8.92 MDM2 MUC1 TP53 TP63

Sources for Pleomorphic Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....